Compare Torrent Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA STRIDES PHARMA SCIENCE TORRENT PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 38.5 42.1 91.6% View Chart
P/BV x 9.8 2.0 496.7% View Chart
Dividend Yield % 0.6 0.2 252.3%  

Financials

 TORRENT PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
TORRENT PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,9641,147 171.2%   
Low Rs1,245642 193.9%   
Sales per share (Unadj.) Rs453.4317.2 142.9%  
Earnings per share (Unadj.) Rs25.87.8 328.7%  
Cash flow per share (Unadj.) Rs62.325.1 248.6%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.10.2 473.9%  
Book value per share (Unadj.) Rs279.2274.3 101.8%  
Shares outstanding (eoy) m169.2289.50 189.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.52.8 125.5%   
Avg P/E ratio x62.2114.0 54.6%  
P/CF ratio (eoy) x25.835.7 72.2%  
Price / Book Value ratio x5.73.3 176.2%  
Dividend payout %65.925.5 258.6%   
Avg Mkt Cap Rs m271,51380,058 339.1%   
No. of employees `00013.62.5 542.4%   
Total wages/salary Rs m14,0384,341 323.4%   
Avg. sales/employee Rs Th5,642.611,325.8 49.8%   
Avg. wages/employee Rs Th1,032.41,731.4 59.6%   
Avg. net profit/employee Rs Th320.9280.1 114.6%   
INCOME DATA
Net Sales Rs m76,72828,394 270.2%  
Other income Rs m571941 60.7%   
Total revenues Rs m77,29929,334 263.5%   
Gross profit Rs m19,8313,965 500.1%  
Depreciation Rs m6,1771,540 401.0%   
Interest Rs m5,0381,962 256.7%   
Profit before tax Rs m9,1871,403 654.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m-3,570-436 819.2%   
Tax Rs m1,25497 1,288.3%   
Profit after tax Rs m4,363702 621.4%  
Gross profit margin %25.814.0 185.1%  
Effective tax rate %13.66.9 196.8%   
Net profit margin %5.72.5 230.0%  
BALANCE SHEET DATA
Current assets Rs m50,37524,836 202.8%   
Current liabilities Rs m51,65318,993 272.0%   
Net working cap to sales %-1.720.6 -8.1%  
Current ratio x1.01.3 74.6%  
Inventory Days Days9271 129.7%  
Debtors Days Days68113 60.2%  
Net fixed assets Rs m83,64834,289 244.0%   
Share capital Rs m846895 94.5%   
"Free" reserves Rs m46,39723,651 196.2%   
Net worth Rs m47,24424,546 192.5%   
Long term debt Rs m39,12915,513 252.2%   
Total assets Rs m141,20965,437 215.8%  
Interest coverage x2.81.7 164.6%   
Debt to equity ratio x0.80.6 131.0%  
Sales to assets ratio x0.50.4 125.2%   
Return on assets %6.74.1 163.5%  
Return on equity %9.22.9 322.9%  
Return on capital %12.36.9 178.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,10315,697 140.8%   
Fx outflow Rs m5,522735 750.8%   
Net fx Rs m16,58114,962 110.8%   
CASH FLOW
From Operations Rs m17,9811,871 961.2%  
From Investments Rs m-2,4135,826 -41.4%  
From Financial Activity Rs m-13,145-10,157 129.4%  
Net Cashflow Rs m2,380-2,615 -91.0%  

Share Holding

Indian Promoters % 71.5 27.7 258.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 37.8 18.6%  
FIIs % 12.6 8.6 146.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 25.9 34.0%  
Shareholders   26,511 56,241 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   J.B.CHEMICALS  SUVEN LIFE SCIENCES  WYETH  CADILA HEALTHCARE  VENUS REMEDIES  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 14, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS